AI assistant
FDC Ltd. Earnings Release 2022
60812_rns_2022-05-26_5df7b0a6-2614-495f-bd78-cabb44473f56.pdf
Earnings Release
Open in viewerOpens in your device viewer
MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS
Date:- May 26, 2022
To, SSELimited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001
National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051
SSEScript Code: 531599 NSE Symbol: FDC
Sub: Press Release on Q4-FY 22 and 12M-FY22 Results.
Dear Sir/Madam,
Please find attached herewith the Press Release issued in relation to the Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Year ended March 31, 2022.
Kindly take the same on record.
Thanking you,
Vars IKatre Company Secretary & Compliance Officer M. No.: FCS-8948
| CORPORATE OFFICE |
: 142-48, S. V. Road, Jogeshwari tyV), Mumbai - 400 102. INDIA |
|---|---|
| Tel.: +91-22-6291 7900/950/26780652/2653/2656. Fax: +91-22-2677 3462 E-mail: [email protected] • Website: www.fdcindia.com |
|
| REGISTERED OFFICE |
: 8-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA |
| Tel.: 0240-2554407/2554299/2554967 • Fax: 0240-255 4299 |
|
| E-mail: [email protected] • CIN : L24239MH1940PLC003176 |
MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS
Foe Limited reports Q4FY22 results
Mumbai, zs" May, 2022: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258BOI022) reported financials for the fourth quarter and financial year ending 31st March 2022.
| Rs. in lakhs |
Q4' 21-22 |
Q4' 20-21 |
% YOY Growth |
|---|---|---|---|
| Operating Revenues |
34,105 | 31,340 | 9% |
| EBITDA | 2,888 | 6,658 | -57% |
| EBITDA % |
8% | 21% | |
| PBT | 1,897 | 5,385 | -65% |
| PAT | 1,039 | 4,676 | -78% |
| EPS | 0.62 | 2.77 | -78% |
Consolidated Q4FY22 and FY22 FDC reported:
| Rs. in lakhs |
FY22 | FY21 | % YOY Growth |
|---|---|---|---|
| Operating Revenues |
1,52,792 | 1,33,320 | 15% |
| EBITDA | 32,978 | 43,108 | -23% |
| EBITDA % |
22% | 32% | |
| PBT | 28,939 | 38,771 | -25% |
| PAT | 21,616 | 30,120 | -28% |
| EPS | 12.81 | 17.72 | -28% |
Commenting on the results;
Overall for FY22 the company has registered healthy growth which is evident from the higher double-digit number, this is backed by strong performance of our Domestic business, which contributes to almost 86% of Sales. This was due to the robust demand across our established therapies and brands leading to 31 % revenue growth. We experienced slowdown in our USA business because of price erosion and lower demand for current products due to re-entry of competitors. The good news is that our partners have been successful in maintaining meaningful market share.
We have experienced the heat of increased cost, as experienced by every player in the Industry. This can be seen by increases in RM/PM as well as Logistics and Marketing costs in the period FY22. Additionally, profits have also taken a hit because of Covid-19 related material destruction which is a one-time effect in Q4FY22. Constant efforts are being made by your company to improve operational efficiency and product mix to improve margins.
-
- INDIA Tel.: +91-22-3071 9100 - 399 / 26780652/2653/2656 • Fax: +91-22-26786393/81 E-mail: [email protected] • Website: www.fdcindia.com : 8-8, M.ID.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA Tel.: 0240-2554407/2554299/2554967 • Fax: 0240-2554299 CORPORATE REGISTERED OFFICE
E-mail: waluj@fdcindiacom • CIN : L24239MH1940PLC003176
Foe Limited
India Market:
Highlights:
- Q4FY22 revenue at Rs. 278.38 Crore, up 18% YOY
- FY22 revenue at Rs. 1,304.44 Crore, up 31% YOY
As per secondary sales data by IQVIA for the period MAT Mar'22, the Company delivered a strong YoY growth of 19% compared to Indian Pharmaceutical Market (IPM) growth of 18% YoY. This growth was mainly driven by Big brands like Ziti, Electral, Enerzal and Zathrin which witnessed a good volume growth.
FDC has moved one rank up from 23rd in MAT Mar'21 to 22nd in MAT Mar'22 in IPM. On MAT Mar'22, Ziti's rank has moved to 39th largest brand in IPM from 53rd in the same period last year while Electral has moved up to 40th in IPM from 43rd in the same period last year.
Export Formulations Market:
Highlights:
- Q4FY22 revenue at Rs. 47.28 Crores, down 17% YOY
- FY22 revenue at Rs. 163.27 Crores, down 39% YOY
We have received registration for Electral in several countries, this is in line with our efforts of making Electral a global brand across territories.
Export API Market:
Highlights:
- Q4FY22 revenue at Rs.14.35 Crores, down 24% YOY
- FY22 revenue at Rs. 55.95 Crores, down 8% YOY
ABOUT FDC LTD
FDC was established in the year 1940, with the vision of building a world class company while contributing to making the nation self-reliant in healthcare. FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE, to cite a few. FDC is a forerunner in manufacturing and marketing of Oral Rehydration Salts (ORS), anti-infectives and Ophthalmics. FDC has also set-up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients (APIs) as well as Finished Dosage Forms. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Vema in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modem technology, empowering talent and expanding healthcare horizons for a better quality of life to millions globally.
Disclaimer
Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.
Registered Office: Waluj, Aurangabad, Maharashtra-431 136. India'
